Jens Wiebe

Dr. Jens Wiebe

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2018 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
HNHolger Nef
Holger Nef
JWJens Wiebe
Jens Wiebe
NBNiklas Boeder
Niklas Boeder
ODOliver Dörr
Oliver Dörr
TBTimm Bauer
Timm Bauer
CHChristian Hamm
Christian Hamm

1 January 2015 in International Journal of Cardiology
Verified
Journal Article
Closed access
PDF file
JWJens Wiebe
Jens Wiebe
CLChristoph Liebetrau
Christoph Liebetrau
ODOliver Dörr
Oliver Dörr
AMAstrid Most
Astrid Most
KWKay Weipert
Kay Weipert
HNHolger M. Nef
Holger M. Nef

11 December 2013 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
JWJens Wiebe
Jens Wiebe
SBStefan Bertog
Stefan Bertog
JFJennifer Franke
Jennifer Franke
OWOlga Wettstein
Olga Wettstein
KLKatharina Lehn
Katharina Lehn
HSHorst Sievert
Horst Sievert

1 October 2020 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
JWJens Wiebe
Jens Wiebe
CKConstantin Kuna
Constantin Kuna
TITareq Ibrahim
Tareq Ibrahim
MLMartin Lösl
Martin Lösl
SCSalvatore Cassese
Salvatore Cassese
AKAdnan Kastrati
Adnan Kastrati

19 January 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JWJens Wiebe
Jens Wiebe
GNGjin Ndrepepa
Gjin Ndrepepa
SKSebastian Kufner
Sebastian Kufner
ALAnna L. Lahmann
Anna L. Lahmann
EXErion Xhepa
Erion Xhepa
SCSalvatore Cassese
Salvatore Cassese
Background: The clinical impact of early aspirin discontinuation compared with dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention with stenting remains poorly studied. We investigated the clinical outcomes of patients assigned to either early aspirin discontinuation or DAPT after percutaneous coronary intervention with stenting. Methods and Results: We performed a meta‐analysis of aggregate data from randomized clinical trials enrolling participants receiving a percutaneous coronary intervention with stenting and assigned to either early aspirin discontinuation or DAPT. Scientific databases were searched from inception through March 30, 2020. Trial‐level hazard ratios (HRs) and 95% CIs were pooled using a random effects model with inverse variance weighting. The primary outcome was all‐cause death. Secondary outcomes were myocardial infarction, stent thrombosis, stroke, and major bleeding. Overall, 36 206 participants were allocated to either early aspirin discontinuation (experimental therapy, n=18 088) or DAPT (control therapy, n=18 118) in 7 trials. Median follow‐up was 12 months. All‐cause death occurred in 2.5% of patients assigned to experimental and 2.9% of patients assigned control therapy (hazard ratio [HR], 0.91, 95% CI, 0.75–1.11; P =0.37). Overall, patients treated with experimental versus control therapy showed no significant difference in terms of myocardial infarction (HR, 1.02 [0.85–1.22], P =0.81), stent thrombosis (HR, 1.02 [0.87–1.20], P =0.83), or stroke (HR, 1.01 [0.68–1.49], P =0.96). However, the risk for major bleeding (HR, 0.58 [0.43–0.77], P <0.01) was significantly reduced by experimental as compared with control therapy. Conclusions: In patients treated with percutaneous coronary intervention and stenting, assigned to a strategy of early aspirin discontinuation versus DAPT, the risk of death and ischemic events is not significantly different but the risk of bleeding is lower.

1 December 2015 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Closed access
JWJens Wiebe
Jens Wiebe
CLChristoph Liebetrau
Christoph Liebetrau
ODOliver Dörr
Oliver Dörr
EWEva Wilkens
Eva Wilkens
TBTimm Bauer
Timm Bauer
HNHolger M. Nef
Holger M. Nef